H.R. 679 — To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.

H.R. 679 — To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes. | JustPolicyThe main purpose of this legislation is to reverse changes made by the Food and Drug Administration (FDA) in January 2023 regarding the risk evaluation and mitigation strategy (REMS) for the abortion pill mifepristone. The objective is to restore the previous regulations governing the use of this medication. Key provisions of the legislation include the outright nullification of the FDA's 2023 modifications to the REMS for mifepristone.